[Important Notice](index=1&type=section&id=%E4%B8%80%E3%80%81%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) [Dividend Distribution Plan](index=1&type=section&id=1.1%20%E8%82%A1%E6%81%AF%E5%88%86%E9%85%8D%E9%A0%90%E6%A1%88) The Board resolved to distribute a cash dividend of RMB 0.40 per share (tax inclusive) to all shareholders, totaling RMB 650,316,379.60 (tax inclusive), with no bonus shares or capital reserve conversion H1 2025 Dividend Distribution Plan | Indicator | Value | | :--- | :--- | | Cash Dividend Per Share (Tax Incl.) | RMB 0.40 | | Total Share Capital (As of Jun 30, 2025) | 1,625,790,949 shares | | Total Proposed Cash Dividend (Tax Incl.) | RMB 650,316,379.60 | | Bonus Shares | None | | Capital Reserve Conversion to Share Capital | None | [Report Description and Board Statement](index=1&type=section&id=1.2%20%E5%A0%B1%E5%91%8A%E8%AA%AA%E6%98%8E%E8%88%87%E8%91%A3%E4%BA%8B%E6%9C%83%E8%81%B2%E6%98%8E) This summary is extracted from the company's H1 2025 report, with the Board, Supervisory Committee, and senior management guaranteeing its truthfulness, accuracy, and completeness; the financial report for this period is unaudited and prepared under China Accounting Standards, with the Chinese version prevailing - This interim report summary is extracted from the full 2025 interim report, investors are advised to read the full report carefully[5](index=5&type=chunk) - The Board, Supervisory Committee, and their directors, supervisors, and senior management guarantee the truthfulness, accuracy, and completeness of this summary and assume legal responsibility[5](index=5&type=chunk) - The Group's and the company's financial reports for this period are prepared under China Accounting Standards and are unaudited[7](index=7&type=chunk) [Board of Directors Composition](index=1&type=section&id=1.3%20%E8%91%A3%E4%BA%8B%E6%9C%83%E6%88%90%E5%93%A1%E6%A7%8B%E6%88%90) As of the announcement date, the company's Board comprises five executive directors and four independent non-executive directors, all of whom attended the 28th meeting of the Ninth Board of Directors - Board members include executive directors Li Xiaojun, Cheng Ning, Cheng Hongjin, Tang Heping, Li Hong, and independent non-executive directors Chen Yajin, Huang Min, Huang Longde, Sun Baoqing[5](index=5&type=chunk) - All directors attended the 28th meeting of the Ninth Board of Directors, with three independent non-executive directors participating via telecommunication[5](index=5&type=chunk) [Definitions](index=2&type=section&id=%E4%BA%8C%E3%80%81%E9%87%8B%E7%BE%A9) This section defines common terms used in the report, including company names, geographical areas, reporting periods, group entities, management bodies, regulatory agencies, and business-related professional terms Definitions of Key Terms | Term | Definition | | :--- | :--- | | Company/This Company/GPHL Baiyunshan | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | | Reporting Period | January 1, 2025 to June 30, 2025 | | GPHL | Guangzhou Pharmaceutical Group Co., Ltd., the company's controlling shareholder | | S2B2C | Suppliers to Business to Customers, a one-stop service system from industry to business to end-users, directly reaching individual consumers | | ERP | Enterprise Resource Planning, an information technology-based systematic management platform | | SPD | Supply Processing Distribution, a medical SPD supply chain management model | [Company Profile](index=5&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) [Company Introduction](index=5&type=section&id=3.1%20%E5%85%AC%E5%8F%B8%E7%B0%A1%E4%BB%8B) The company is listed on the Shanghai Stock Exchange (A-shares) and The Stock Exchange of Hong Kong Limited (H-shares) under the stock name 'Baiyunshan', with contact information for the Board Secretary and Securities Affairs Representative, along with registered address and website Company Listing Information | Indicator | A-shares | H-shares | | :--- | :--- | :--- | | Stock Abbreviation | Baiyunshan | Baiyunshan | | Stock Code | 600332 | 00874 | | Listing Exchange | Shanghai Stock Exchange | The Stock Exchange of Hong Kong Limited | - The company's registered and office address is No. 45 Shamian North Street, Liwan District, Guangzhou, Guangdong Province, China, and its principal place of business in Hong Kong is Room 2005, 20th Floor, Tower 2, Lippo Centre, 89 Queensway, Hong Kong[11](index=11&type=chunk) [Key Accounting Data and Financial Indicators](index=6&type=section&id=3.2%20%E4%B8%BB%E8%A6%81%E6%9C%83%E8%A8%88%E6%95%B8%E6%93%9A%E5%92%8C%E8%B2%A1%E5%8B%99%E6%8C%87%E6%A8%99) During the reporting period, the company's operating revenue increased by 1.93% year-on-year, but total profit and net profit attributable to parent company shareholders decreased by 4.30% and 1.31% respectively; net cash flow from operating activities significantly dropped by 66.79% due to lower cash collection and increased procurement payments, while net assets and total assets continued to grow Key Accounting Data (Current Period vs. Prior Period) | Indicator | Current Period (RMB Yuan) | Prior Period (RMB Yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 41,834,546,114 | 41,042,815,088 | 1.93 | | Total Profit | 3,090,416,329 | 3,229,403,377 | (4.30) | | Net Profit Attributable to Parent Company Shareholders | 2,516,140,987 | 2,549,565,302 | (1.31) | | Net Cash Flow from Operating Activities | (3,397,136,268) | (2,036,740,495) | (66.79) | Key Financial Indicators (Current Period vs. Prior Period) | Indicator | Current Period | Prior Period | YoY Change | | :--- | :--- | :--- | :--- | | Basic EPS (RMB/share) | 1.548 | 1.568 | (1.31)% | | Diluted EPS (RMB/share) | 1.548 | 1.568 | (1.31)% | | Weighted Average ROE (%) | 6.77 | 7.04 | Decrease of 0.27 percentage points | - Net cash flow from operating activities decreased by **66.79%** year-on-year, primarily due to lower cash collection and increased procurement payments[14](index=14&type=chunk) [Top Ten Shareholders' Holdings](index=8&type=section&id=3.3%20%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E6%9D%B1%E6%8C%81%E8%82%A1%E6%83%85%E6%B3%81) As of the end of the reporting period, the company had 85,550 shareholders; controlling shareholder GPHL held 45.04% of shares, and HKSCC Nominees Limited was the second largest shareholder with 13.52% - As of the end of the reporting period, the total number of shareholders was **85,550 households**[15](index=15&type=chunk) Top Ten Shareholders' Holdings | Shareholder Name | Shareholder Type | Approx. % of Total Share Capital | Number of Shares Held | | :--- | :--- | :--- | :--- | | GPHL | State-owned Legal Person | 45.04 | 732,305,103 | | HKSCC Nominees Limited | Overseas Legal Person | 13.52 | 219,783,142 | | Guangzhou Chengfa | Other | 4.16 | 67,576,183 | | China Securities Finance Corporation Limited | State-owned Legal Person | 2.91 | 47,277,962 | [Preferred Shareholder Information](index=9&type=section&id=3.4%20%E5%84%AA%E5%85%88%E8%82%A1%E8%82%A1%E6%9D%B1%E6%83%85%E6%B3%81) As of the end of the reporting period, the company had no preferred shareholders - As of the end of the reporting period, the company had no preferred shareholders[17](index=17&type=chunk) [Changes in Controlling Shareholder or Actual Controller](index=9&type=section&id=3.5%20%E6%8E%A7%E

Group 1 - The stock price of Baiyunshan is reported at 26.78 yuan as of August 13, 2025, with a slight decrease of 0.03 yuan, representing a drop of 0.11% from the previous trading day [1] - Baiyunshan's main business includes the research and manufacturing of traditional Chinese and Western medicines, chemical raw materials, biomedicine, as well as health products and medical services [1] - The company holds significant brands such as Wanglaoji and Chen Lijie, establishing an important position in the pharmaceutical industry [1] Group 2 - Former chairman Li Chuyuan and former director Zhang Chunbo of Baiyunshan and Guangzhou Pharmaceutical Group are under investigation for alleged illegal activities, including inflating drug prices and corruption in brand authorization management [1] - This case is highlighted as a significant incident within the recent anti-corruption campaign in the pharmaceutical sector [1] Group 3 - On August 13, Baiyunshan experienced a net outflow of 680,200 yuan in principal funds, with a cumulative net outflow of 7,958,900 yuan over the past five days [1]

金融界消息 截至2025年8月11日收盘，白云山（600332）报收于26.75元，上涨0.26%，换手率0.55%， 成交量7.77万手，成交金额2.07亿元。 资金流向方面，今日主力资金净流出1842.55万元，占比成交额8.88%。其中，超大单净流出2579.70万 元、占成交额12.43%，大单净流入737.15万元、占成交额3.55%，中单净流出流入1474.90万元、占成交 额7.11%，小单净流入367.66万元、占成交额1.77%。 白云山最新一期业绩显示，截至2025一季报，公司营业总收入224.73亿元、同比减少2.06%，归属净利 润18.21亿元，同比减少6.99%，扣非净利润16.75亿元，同比减少8.67%，流动比率1.542、速动比率 1.242、资产负债率50.48%。 天眼查商业履历信息显示，广州白云山医药集团股份有限公司，成立于1997年，位于广州市，是一家以 从事医药制造业为主的企业。企业注册资本162579.0949万人民币，实缴资本73230.5103万人民币。公司 法定代表人为李小军。 通过天眼查大数据分析，广州白云山医药集团股份有限公司共对外投资了57家企业，参与 ...

Core Viewpoint - The conference held on August 9 by Guangzhou Pharmaceutical Baiyunshan focused on the latest research breakthroughs of Xingqun Ertian Oil in the field of mosquito repellent and discussed the protection of traditional Chinese medicine heritage culture [1] Group 1 - The conference highlighted the advancements in mosquito repellent research related to Xingqun Ertian Oil [1] - The event included an academic discussion on the protection of intangible cultural heritage related to traditional Chinese medicine [1]

Group 1 - The company activated its emergency response mechanism promptly in response to disaster situations, assessing the needs of affected areas and quickly dispatching targeted medicines [1][2] - In Guizhou's Rongjiang and Sandu, the company completed the preparation and distribution of emergency medicines and supplies worth 500,000 yuan within 48 hours, including 2,750 boxes of Baiyunshan Cold Medicine Granules and 9,600 medical masks [1] - The company provided over 6,500 targeted medicines to Huaihua's Yuanling County in Hunan, demonstrating its commitment to disaster relief efforts [1] Group 2 - The company collaborated with national strategic partners to support flood relief efforts, donating nearly 1 million yuan worth of medicines and supplies to affected areas, military personnel, and veterans [2] - The company emphasized the use of traditional Chinese medicine to build a robust "health barrier" during the disaster response [2]

天眼查商业履历信息显示，广州白云山医药集团股份有限公司，成立于1997年，位于广州市，是一家以 从事医药制造业为主的企业。企业注册资本162579.0949万人民币，实缴资本73230.5103万人民币。公司 法定代表人为李小军。 通过天眼查大数据分析，广州白云山医药集团股份有限公司共对外投资了57家企业，参与招投标项目 491次，知识产权方面有商标信息2450条，专利信息26条，此外企业还拥有行政许可83个。 金融界消息 截至2025年8月8日收盘，白云山（600332）报收于26.68元，下跌0.07%，换手率0.41%，成 交量5.71万手，成交金额1.53亿元。 资金流向方面，今日主力资金净流出1261.69万元，占比成交额8.27%。其中，超大单净流出534.90万 元、占成交额3.51%，大单净流出726.79万元、占成交额4.76%，中单净流出流出87.10万元、占成交额 0.57%，小单净流入1348.79万元、占成交额8.84%。 白云山最新一期业绩显示，截至2025一季报，公司营业总收入224.73亿元、同比减少2.06%，归属净利 润18.21亿元，同比减少6.99%，扣非净利润16.7 ...

来源：新华社 山体滑坡发生后，广州市成立现场指挥部，迅速组织调集精锐专业力量，全力以赴做好抢险救援、伤员 救治、人员转移等各项工作。 截至8月6日17时，白云区共出动应急、消防、公安、住建、卫健、供电、城管、水务等救援力量607人 次，调集生命探测仪、液压扩张器、挖掘机等专业救援设备733台，调集11家医院救护车10车次56人参 与救治，调拨帐篷、雨衣等应急、防疫物资2200份，排查周边区域，妥善做好群众转移工作。 目前，搜救工作仍在紧张进行中。 转自：北京日报客户端 记者从广州市白云区应急管理局获悉，6日8时30分许，由于连日大雨造成山体滑坡，致大源街大源村黄 庄片区房屋受损。截至6日17时，14名被困人员中已救出7名并送医院救治，周边地区996名居民全部转 移安置。 作者: 胡拿云 王瑞平 ...

Group 1 - The article discusses the outbreak of Chikungunya fever, an acute mosquito-borne infectious disease characterized by high fever above 39°C, severe joint pain, and rashes, with no effective vaccine currently available [1] - The National Health Commission has recommended "acetaminophen" as a preferred antipyretic and analgesic to alleviate key symptoms in the "Chikungunya Fever Diagnosis and Treatment Plan (2025 Edition)" [1] - The Foshan Market Supervision Administration has implemented a real-name registration sales system for 47 types of drugs during the epidemic prevention period, including key controlled medicines for managing fever and joint pain [1] Group 2 - Guangzhou Pharmaceutical Group's subsidiary, Baiyunshan, highlighted the value of traditional Chinese medicine products, such as Baiyunshan Cold Medicine Granules, which contain acetaminophen to effectively relieve high fever, headaches, and body aches [2] - Baiyunshan has established GAP (Good Agricultural Practices) bases for the cultivation of medicinal materials, ensuring the safety, quality, and stability of the ingredients used in their products [2] - The sales of mosquito repellent products in Guangzhou, Shenzhen, and Foshan have surged over 200% in the past week, indicating a significant increase in consumer demand for mosquito prevention [3]

文｜证券之星 刘凤茹 近日，白云山公告(600332.SH)拟作为有限合伙人以斥资近15亿元参与设立广州广药基金二期股权投资 合伙企业(有限合伙)(简称"广药基金二期")，后者通过直接或间接的方式开展生物医药领域的股权投 资。白云山此举意在加速布局生物医药健康产业。 证券之星注意到，作为老牌药企，白云山正深陷"2024年归母净利同比下滑三成，创2017年以来新低"的 业绩困局。这背后是明星产品"金戈"销售滑坡、王老吉凉茶式微及对一心堂股权投资计提3.86亿减值的 三锤重击。今年一季度白云山营利双降持续承压，如何走出业绩低谷，是新董事长李小军面临的新课 题。 净利落入七年"谷底"，加速布局生物医药健康 根据公告，广药基金二期的设立结构为：白云山认缴14.985亿元广药基金二期份额，占比99.9%；广州 广药资本私募基金管理有限公司("广药资本")认缴0.015亿元广药基金二期份额，占比0.1%。该基金存续 期为13年，其中投资期10年，退出期3年。 据悉，广药基金二期的管理人为广药资本，后者是白云山控股股东广州医药集团有限公司持股80%的控 股子公司，公司副董事长程宁担任广药资本的董事长。白云山此次认购广药基金 ...

金融界消息 截至2025年8月5日收盘，白云山（600332）报收于26.94元，下跌0.37%，换手率0.66%，成 交量9.21万手，成交金额2.48亿元。 通过天眼查大数据分析，广州白云山医药集团股份有限公司共对外投资了57家企业，参与招投标项目 491次，知识产权方面有商标信息2450条，专利信息26条，此外企业还拥有行政许可83个。 资金流向方面，今日主力资金净流出1420.11万元，占比成交额5.72%。其中，超大单净流出1679.22万 元、占成交额6.76%，大单净流入259.11万元、占成交额1.04%，中单净流出流入68.20万元、占成交额 0.27%，小单净流入1351.90万元、占成交额5.44%。 来源：金融界 白云山最新一期业绩显示，截至2025一季报，公司营业总收入224.73亿元、同比减少2.06%，归属净利 润18.21亿元，同比减少6.99%，扣非净利润16.75亿元，同比减少8.67%，流动比率1.542、速动比率 1.242、资产负债率50.48%。 天眼查商业履历信息显示，广州白云山医药集团股份有限公司，成立于1997年，位于广州市，是一家以 从事医药制造业为主的企业 ...